Cardiff Oncology
CRDF on Nasdaq. Market value $89m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 104 funds in all.
Largest holders overall
- Laurion Capital Management LP$4mAdded
- Vanguard Capital Management$4m
- Pfizer$3m
- Franklin Resources$2m
- BlackRock$1mCut
- Blair William$1m
- Geode Capital Management$1mCut
- UBS Group AG$830,309Added
- Jane Street Group$790,270Added
- Vanguard Fiduciary Trust$533,783Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
No one has reported a stake above 5% since December 2024.
- Pfizer Inc. 13-5315170Passive investorSold down below 5%Since 31 December 2024
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
- Commodore Capital LPPassive investorSold down below 5%Since 30 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
Pfizer Inc. 13-5315170 Passive investor | Sold down below 5% | 31 December 2024 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 | |
Commodore Capital LP Passive investor | Sold down below 5% | 30 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $1m of shares on the open market.
- PACE GARY WDirectorBought
- Date
- 14 July 2026
- Shares
- 687,285
- Price
- $1.46
- Value
- $1,000,000
- Mohindru ManiChief Executive Officer, DirectorBought
- Date
- 14 July 2026
- Shares
- 34,364
- Price
- $1.46
- Value
- $50,000
- Mohindru ManiChief Executive Officer, DirectorBought
- Date
- 18 June 2026
- Shares
- 24,703
- Price
- $1.21
- Value
- $29,891
- PACE GARY WDirectorBought
- Date
- 18 June 2026
- Shares
- 30,000
- Price
- $1.22
- Value
- $36,600
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 14 July 2026 | PACE GARY W Director | Bought | 687,285 | $1.46 | $1,000,000 |
| 14 July 2026 | Mohindru Mani Chief Executive Officer, Director | Bought | 34,364 | $1.46 | $50,000 |
| 18 June 2026 | Mohindru Mani Chief Executive Officer, Director | Bought | 24,703 | $1.21 | $29,891 |
| 18 June 2026 | PACE GARY W Director | Bought | 30,000 | $1.22 | $36,600 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Cardiff Oncology’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Feb 2026, plus the 10-Q filed 11 Aug 2026 and 11 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”
Show the full paragraph
The Company has incurred net losses since its inception and has negative operating cash flows. As of June 30, 2026, the Company had $ 34.5 million in cash, cash equivalents and short-term investments, which is not sufficient to meet its funding requirements for at least the next 12 months following the filing of this Form 10-Q. Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
From the 10-Q filed 11 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.